World

Regeneron, Lilly Reveal Positive Results for Antibody Combos

Regeneron treatment prevented all Covid symptoms in analysis
Therapies could be needed amid slow vaccinations, new strains

Regeneron Pharmaceuticals Inc. signage is displayed outside their headquarters in Tarrytown, N.Y., U.S., on June 12, 2020. Regeneron Pharmaceuticals Inc. said it had begun human trials of a new antibody cocktail for Covid-19, part of an ambitious clinical-testing plan that could lead to a new treatment option by the end of summer if all goes well.Photographer: Michael Nagle/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Emma Court and Tim Loh

January 26, 2021 at 12:00 PM UTC

Updated on

January 26, 2021 at 8:10 PM UTC

This article is for subscribers only.

Regeneron Pharmaceuticals Inc. and Eli Lilly and Co. each reported positive results from Covid-19 antibody drug combinations Tuesday, as both companies seek to expand use of their therapies and ensure effectiveness against new strains.

Regeneron said its antibody cocktail reduced Covid-19 cases by half and prevented all symptoms in people at high risk of catching the coronavirus. A combination of two antibodies that Lilly’s advancing to combat new variants cut the chances of hospitalizations and deaths by 70% in high-risk patients.